Age-related phenotypes in breast cancer: A population-based study

  • 0Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway.

|

|

Summary

This summary is machine-generated.

Young women under 40 experience more aggressive breast cancer with higher proliferation. This suggests unique biological features in young patients may offer new treatment opportunities.

Area Of Science

  • Oncology
  • Pathology
  • Genetics

Background

  • Breast cancer in women under 40 often presents with aggressive subtypes and poorer outcomes.
  • The underlying biological differences contributing to this disparity remain incompletely understood.

Purpose Of The Study

  • To investigate the relationship between age and breast cancer biology, focusing on tumor cell proliferation.
  • To compare the biological features of breast cancer in young (<40 years) versus older (50-69 years) patient cohorts.

Main Methods

  • Comparative analysis of clinico-pathologic data, immunohistochemical markers (including Ki67), and survival outcomes.
  • Utilized two cohorts: Bergen cohort-1 (<50 years, n=355) and Bergen cohort-2 (50-69 years, n=540).
  • Examined differences in tumor subtypes, hormone receptor status, HER2 status, and lymph node metastasis.

Main Results

  • Younger patients (<40) exhibited more aggressive features: hormone receptor negativity, HER2 positivity, lymph node metastasis, and higher rates of HER2-enriched and triple-negative subtypes.
  • Age <40 was significantly associated with increased tumor cell proliferation, measured by Ki67.
  • Ki67 demonstrated reduced prognostic value in younger breast cancer patients compared to older cohorts.

Conclusions

  • Breast cancer in young women (<40) is characterized by aggressive phenotypes and heightened tumor cell proliferation.
  • These distinct biological characteristics in younger patients may necessitate age-specific treatment strategies.
  • Further research into these unique biological features could reveal novel therapeutic targets and improve patient outcomes.